Dimensional Fund Advisors LP reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 13.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 547,857 shares of the medical research company’s stock after selling 88,083 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.15% of Charles River Laboratories International worth $55,417,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in CRL. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Charles River Laboratories International by 12.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after purchasing an additional 202 shares during the period. Riverhead Capital Management LLC raised its holdings in Charles River Laboratories International by 14.7% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after purchasing an additional 247 shares during the period. Cambridge Advisors Inc. bought a new position in Charles River Laboratories International in the 2nd quarter worth $202,000. Advisor Partners LLC bought a new position in Charles River Laboratories International in the 2nd quarter worth $208,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in Charles River Laboratories International in the 2nd quarter worth $217,000. 95.08% of the stock is currently owned by institutional investors.

A number of equities analysts recently commented on the company. Credit Suisse Group reaffirmed a “neutral” rating and issued a $112.00 target price (up from $95.00) on shares of Charles River Laboratories International in a report on Monday. Jefferies Group LLC raised their target price on Charles River Laboratories International from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, October 9th. Robert W. Baird reaffirmed a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a report on Friday, September 1st. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 target price on the stock. Finally, BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 22nd. Six investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Charles River Laboratories International has an average rating of “Buy” and an average price target of $102.05.

In other Charles River Laboratories International news, insider Davide Molho sold 6,165 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $110.00, for a total value of $678,150.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William D. Barbo sold 4,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $99.91, for a total transaction of $399,640.00. Following the completion of the transaction, the insider now owns 20,424 shares of the company’s stock, valued at approximately $2,040,561.84. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,699 shares of company stock valued at $1,892,393. Insiders own 2.20% of the company’s stock.

Shares of Charles River Laboratories International, Inc. (CRL) opened at 114.23 on Wednesday. The company has a market capitalization of $5.44 billion, a PE ratio of 30.10 and a beta of 0.96. The firm’s 50-day moving average price is $108.17 and its 200-day moving average price is $98.26. Charles River Laboratories International, Inc. has a 12-month low of $67.20 and a 12-month high of $114.50.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. The business had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company’s revenue was up 8.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.20 earnings per share. On average, analysts expect that Charles River Laboratories International, Inc. will post $5.10 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/10/18/dimensional-fund-advisors-lp-sells-88083-shares-of-charles-river-laboratories-international-inc-crl.html.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.